IN THE UNITED STATES PATENT AND TRADEMARK OFFICE			
(0) 40	Atty Dkt. 620-301 C# M#	,	7 A
Davis et al	1647		/ ch
Davis et al Serial No. 10/822,677 (aminer: NICHOLS		
Filed: April 13, 2004	Date: October 7, 2005		
Title: USE OF SECRETIN-RELIGANDS IN T FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE	REATMENT OF CYSTIC PULMONARY DISEASE (COPE))	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
Sir:	SE/AMENDMENT/LETTER		
This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.			
☐ Correspondence Address Indication	Form Attached.		
Fees are attached as calculated below: Total effective claims after amendment 4 n previously paid for 20 (at least 20) =	ninus highest number 0 x \$50.00	\$0.00 (1202)/\$0.00 (2202)	\$
Independent claims after amendment 2 reviously paid for 4 (at least 3) =	ninus highest number 0 x \$200.00	\$0.00 (1201)/\$0.00 (2201)	\$
If proper multiple dependent claims now added for f	irst time, (ignore improper); a	dd	•
		.00 (1251)/\$60.00 (2251) 00 (1252)/\$225.00 (2252) .00 (1253/\$510.00 (2253)	
Terminal disclaimer enclosed, add	\$130	0.00 (1814)/ \$65.00 (2814)	\$
☐ Applicant claims "small entity" status. ☐ Sta	tement filed herewith		
Rule 56 Information Disclosure Statement Filing Fed	e	\$180.00 (1806)	\$
Assignment Recording Fee		\$40.00 (8021)	\$
Other:			\$
		TOTAL FEE ENCLOSED	\$ 1020.00
The Commissioner is hereby authorized to charge any <u>deficiency</u> , or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.			
901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100	NIXON & VANDERHYE P. By Atty: B. J. Sadoff, Reg.		
BJS:pp	Signature:)	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ire Patent Application of

Davis et al

Atty. Ref.: 620-301; Confirmation No. 3671

Appl. No. 10/822,677

TC/A.U. 1647

Filed: April 13, 2004

Examiner: NICHOLS

For: USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC

FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

October 7, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

<u>AMENDMENT</u>

Responsive to the Office Action dated April 8, 2005, entry and consideration of the following amendments and remarks are requested; the period for response having been extended up to and including Monday, October 11, 2005, by submission of the requisite petition and fee, attached.

10/12/2005 HALI11 00000088 10822677

01 FC:1253

1020.00 OP